SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-034827
Filing Date
2023-07-17
Accepted
2023-07-17 17:24:39
Documents
14
Period of Report
2023-07-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc20055975_8k.htm   iXBRL 8-K 28481
2 EXHIBIT 99.1 brhc20055975_ex99-1.htm EX-99.1 20463
6 image00001.jpg GRAPHIC 4251
  Complete submission text file 0001140361-23-034827.txt   198509

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pdsb-20230717.xsd EX-101.SCH 3871
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE pdsb-20230717_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pdsb-20230717_pre.xml EX-101.PRE 16048
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc20055975_8k_htm.xml XML 4239
Mailing Address 25B VREELAND ROAD SUITE 300 FLORHAM PARK NJ 07932
Business Address 25B VREELAND ROAD SUITE 300 FLORHAM PARK NJ 07932 800-208-3343
PDS Biotechnology Corp (Filer) CIK: 0001472091 (see all company filings)

IRS No.: 264231384 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37568 | Film No.: 231092413
SIC: 2834 Pharmaceutical Preparations